Skip to main content
. 2020 Sep 15;10:561598. doi: 10.3389/fonc.2020.561598

FIGURE 2.

FIGURE 2

(A) Fraction of patients with detectable preoperative ctDNA in NSCLC at cancer stage I∼IV. (B) Fraction of patients with detectable postoperative ctDNA in NSCLC at cancer stage I∼IV. (C) Characteristics associated with positive preoperative ctDNA. (D) Negative conversion ratio of preoperative ctDNA at cancer stage I∼III.